Gland Pharma Secures Strategic CDMO Partnership with Global Pharmaceutical Company
Hyderabad: Gland Pharma Limited (NSE: GLAND) announced the execution of a strategic Manufacturing and Supply Agreement (MSA) with a global pharmaceutical company. The partnership involves the technology transfer, manufacturing, and supply of a portfolio of sterile injectable products for international markets.The agreement establishes Gland Pharma as an integrated end-to-end partner to support multiple products throughout various stages of their lifecycle, including both commercially marketed items and pipeline developments. This collaboration follows a full service CDMO model encompassing process development, scale up, validation, commercial manufacturing, technology transfer, and long term supply of sterile injectable products.
The portfolio covers a diversified range of oncology and non-oncology products in Vial, Lyo, Ampoules, and pre filled syringe (PFS) presentations, covering both complex and conventional injectable formulations. Gland Pharma will leverage its comprehensive capabilities—spanning development, technology transfer, manufacturing, quality, and regulatory support—to provide a "one stop" solution to its partner.
Business Scope and Financial Outlook
The agreement is set to provide strong long term business visibility for the company, with revenue generation anticipated starting from calendar year 2029. The current scope covers 55 Stock Keeping Units (SKUs) across three manufacturing sites, with potential for adding more products in the future. Once all products are commercialized, the annualized revenue potential is estimated to be approximately USD 90 - 100 million. Technology transfer activities are planned for completion within two years.Key operational details of the arrangement include:
| Particulars | Detail |
|---|---|
| Arrangement Type | CDMO Partnership / Agreement (MSA) |
| Area of Agreement | International |
| Scope of Business Operation | Full service CDMO model including technology transfer, process development, and commercial manufacturing. |
| Products Covered | Oncology and non oncology injectable formulations in Vial, Lyo, Ampoules, and PFS presentations. |
| Revenue Potential (Annualized) | USD 90 - 100 million after full commercialization. |
Leadership Perspective
Mr. Srinivas Sadu, Executive Chairman of Gland Pharma Limited, stated that the collaboration highlights the confidence global pharmaceutical companies place in the company's development, technology transfer, manufacturing, and supply capabilities. He added that the agreement provides meaningful long term revenue visibility, supports the expansion of their CDMO business, and creates a solid foundation for future growth.Company Overview
Gland Pharma was established in 1978 in Hyderabad and has grown into one of the leading injectable focused companies with a global presence across 60 countries, including markets in Europe, the United States, Canada, Australia, and India. The company operates primarily under a CDMO and business to business (B2B) model. Gland Pharma boasts a wide range of injectables, including vials, ampoules, pre filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. It is also recognized for pioneering Heparin technology in India.GLAND Stock Price Movement
Shares of Gland Pharma Limited slipped by 1.02% on Friday, settling at ₹2601 after shedding ₹26.70 from the previous close. Despite the decline, the share price remained near its 52-week high of ₹2634.30, with a total traded volume of 317,731 shares recorded for the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: